Advanced search
Publication Cover
OncoTargets and Therapy Volume 6, 2013 - Issue
Submit an article Journal homepage
90
Views
17
CrossRef citations to date
0
Altmetric
Short Report

Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas

Naifu Liu1 Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, People’s Republic of China
,
Xiugui Sheng1 Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, People’s Republic of China
,
Yi Liu1 Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, People’s Republic of China
,
Xiaoling Zhang1 Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, People’s Republic of China
&
Jinming Yu2 Shandong Cancer Hospital and Institute, Jinan, Shandong, People’s Republic of ChinaCorrespondence[email protected]
Pages 615-619 | Published online: 05 Jun 2013

References

  • La VecchiaCEpidemiology of ovarian cancer: a summary reviewEur J Cancer Prev200110212512911330452
  • LiuBNashJRunowiczCSwedeHStevensRLiZOvarian cancer immunotherapy: opportunities, progresses and challengesJ Hematol Oncol20103720146807
  • BoursalianTEMcEarchernJALawCLGrewalISTargeting CD70 for human therapeutic useAdv Exp Med Biol200964710811919760069
  • GrewalISCD70 as a therapeutic target in human malignanciesExpert Opin Ther Targets200812334135118269343
  • JunkerKHindermannWvon EggelingFDiegmannJHaesslerKSchubertJCD70: a new tumor specific biomarker for renal cell carcinomaJ Urol200517362150215315879877
  • RyanMCKostnerHGordonKATargeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75Br J Cancer2010103567668420664585
  • AggarwalSHeTFitzhughWImmune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancerGynecol Oncol2009115343043719800108
  • AlleySCOkeleyNMSenterPDAntibody-drug conjugates: targeted drug delivery for cancerCurr Opin Chem Biol201014452953720643572
  • LawCLMcEarchernJAGrewalISNovel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenström’s macroglobulinemiaClin Lymphoma Myeloma200991909319362984
  • LiuNWangXShengXThe clinicopathological characteristics of ‘triple-negative’ epithelial ovarian cancerJ Clin Pathol201063324024320203223
  • ThigpenTA rational approach to the management of recurrent or persistent ovarian carcinomaClin Obstet Gynecol201255111413022343233
  • BanerjeeSKayeSThe role of targeted therapy in ovarian cancerEur J Cancer201147 Suppl 3S116S13021943965
  • OflazogluEStoneIJGordonKPotent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linkerClin Cancer Res200814196171618018809969
  • McEarchernJASmithLMMcDonaghCFPreclinical characterization of SGN-70, a humanized antibody directed against CD70Clin Cancer Res200814237763777219047103

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.